This brief report describes caregiver ratings on the Everyday Cognition (ECog) scale, a psychometrically robust measure of cognitively driven daily activities that was initially designed for other neurodegenerative conditions, in individuals with Parkinson's disease (PD). In 49 individuals with PD, those with suspected PD dementia had more difficulties across ECog domains than those with normal cognition or mild cognitive impairment. Results from multiple regression analyses revealed that activities captured by the ECog were related to measured cognitive ability, over and above disease duration and demographic factors. The lack of floor and ceiling effects speaks to the potential utility of the instrument in practice and research regarding this population. Preliminary data support the utility of the ECog as a marker of functional impact of cognitive problems in PD, though further research will be required to validate the instrument in this population.
C
ognitive dysfunction is common in Parkinson's disease (PD) and is caused by disruptions in frontosubcortical circuits of the brain early in the disease and more diff use cortical changes with disease progression (1) . PD-related cognitive dysfunction can lead to signifi cant impairments in performing daily tasks, and measuring this impairment is important both for clinical practice and as an endpoint for clinical trials (2) . However, to date the fi eld has yet to coalesce around a particular measure of daily functioning in PD. Th e Everyday Cognition (ECog) scale (3) is a potentially attractive measure for this purpose that has established utility in samples with mild cognitive impairment (MCI) and Alzheimer's disease (3, 4) , frontotemporal dementia (5), and prodromal Huntington's disease (6) . However, the ECog's clinical utility in PD has not been explored. Th us, the purpose of the current study was to provide a preliminary evaluation of the ECog in comparison to an established cognitive screening as a fi rst step in validating the ECog for use in PD.
METHOD
Participants were recruited for a broader study on functional abilities in PD from local PD support groups and our movement disorder clinic. To participate in the study, individuals had to have a diagnosis of PD confi rmed by a neurologist, lack other neurological disorders, have a collateral who knew them well enough to be able to complete surveys, and be able to complete other study-related activities. Individuals were excluded from the study if they carried diagnoses of known or suspected atypical parkinsonism or other conditions that could impact their performance. Individuals were tested on their usual medication regimen in the "on" state. Th e data were collected as part of a larger study on functional activities in PD. All study activities were approved by the local institutional review board.
Informants (usually family) were administered the ECog. Th e ECog is an informant-rated questionnaire that comprises 39 items in 6 empirically derived subscales that refl ect complex and cognitively driven daily activities impacted by defi cits in memory, language, visuospatial abilities, and aspects of executive functioning (i.e., planning, organization, and divided attention). Informants utilize a 4-point scale to rate the patient's current level of functioning compared to his or her abilities 10 years ago; a 1 indicates no change while a 4 indicates greatly increased diffi culty (3) . A higher total score on the ECog refl ects greater impairment.
Participants were administered the Montreal Cognitive Assessment (MoCA) (7) while the informants completed surveys separately. Th e MoCA is a validated cognitive screening measure with established sensitivity to cognitive decline in PD (8) . It includes items tapping into a range of cognitive domains including memory, language, visuospatial skills, executive function, attention/concentration, and orientation. A total score ranging from 0 to 30 points is calculated, with higher scores indicating better cognitive performance. Th e MoCA is relatively unaff ected by the motor dysfunction of PD and is a recommended screening tool for cognitive impairment in PD (9) .
To explore the utility of the ECog in this sample, we evaluated scores for fl oor and ceiling eff ects; we also compared ECog
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DISCUSSION
Th e ECog is potentially an attractive daily functioning measure for PD, as it was designed to capture mild diffi culties driven by a variety of cognitive defi cits, including the executive dysfunction that is common in PD. Because the ECog has demonstrated utility in other neurodegenerative processes such as Alzheimer's disease, frontotemporal dementia, and Huntington's disease, it may allow for a common language for evaluating disability related to activities of daily living across populations for research and clinical purposes.
In the current study, ECog scores varied in the expected direction, with increasing levels of dysfunction associated with lower scores on the MoCA. Because physical dysfunction in PD may also impact daily activities, it was encouraging that cognitive dysfunction as measured by the MoCA was a stronger predictor of ECog scores than disease duration (a proxy for motor dysfunction given the accumulation of motor disability with increasing disease duration) or demographic factors. Th is fi nding suggests that the ECog items may be sensitive markers of cognitive dysfunction in PD, over and above the impact of the motor dysfunction of the disease. It is important to note, though, that the lack of a direct motor measure makes this conclusion only tentative at this time.
Capturing day-to-day diffi culties is critical for clinical and research studies of PD MCI and dementia; also, caregivers of individuals with PD seem to be able to parse the diff erence between the motor versus cognitive impact of the disease (11) . Th e ECog thus provides an attractive measure to capture this critical information about functional diffi culties while also avoiding fl oor and ceiling eff ects. Th is is an important consideration in a measure if it is to capture change in functional abilities over time or as a result of an intervention. scores between MoCA-defi ned groups based on recommended cutpoints for PD-related cognitive impairment (8) . Because of the small sample sizes and nonnormal distribution of some variables, we utilized the nonparametric Kruskal-Wallis equality of populations rank test with Dunn's pairwise comparisons for this analysis.
We also explored whether measured cognitive abilities predicted ECog scores over and above age, education, and disease duration. Disease duration, which is associated with increasing disability in PD, was utilized as a proxy of the accumulative motor dysfunction of PD. Th e Hoehn and Yahr score confl ates independence and motor dysfunction in its ratings and thus would have confounded the interpretation of functional impairment and motor dysfunction (10) .
RESULTS
Th e sample consisted of 49 community-dwelling individuals (33 male) with PD. Participants were an average age of 72 years (SD = 8.0), had 14 years of education (SD = 1.4), and were primarily Caucasian (n = 47). Most individuals had moderateseverity disease as measured by the Hoehn and Yahr scale (I, 25%; II, 27%; III, 41%; IV, 6%; and V, 2%). Informants primarily resided with and saw the patient daily (96%) and were predominantly spouses (86%) and lived with the patient (96%). Of the sample, 12 individuals had normal MoCA scores, 24 were probable MCI (MoCA ≥21, <26), and 13 had probable dementia (MoCA <21).
Descriptive statistics for the ECog and the constituent subscales can be found in the Table. Only one caregiver in our sample rated an individual as having no diffi culties on any of the items, while none of the respondents was rated at the ceiling for the items.
Individuals with probable dementia, as defi ned by the MoCA, demonstrated lower scores (P < 0.05) on the ECog total score and all domain scores with the exception of visuospatial skills, divided attention, and organization. Th e latter showed a trend in the expected direction (P = 0.06). In our small sample, MCI and normal control participants did not diff er significantly on the ECog. Hierarchical multiple regression analysis was used to test if MoCA predicted ECog abilities over and Th e fi nding that ECog scores did not diff er between individuals with probable MCI and normal cognition is not surprising. MCI exists as a transitional state between normal cognition and dementia. By defi nition, those with MCI lack signifi cant impairment in daily activities attributable to cognitive decline (9) . Furthermore, some individuals with normal MoCA scores may indeed be having signifi cant cognitive decline, which would only be quantifi ed on more detailed neuropsychological testing, leading to further overlap between these groups. Further work will help clarify the relationship between milder levels of cognitive decline and daily diffi culties as measured by the ECog.
Th is study has several limitations, including the lack of more detailed ratings of motor dysfunction, cognitive dysfunction, and formal clinical diagnoses of dementia and MCI. While the MoCA is a quick assessment and gross measure of cognition, it is possible that it may over-or underestimate cognitive dysfunction. For example, the MoCA was observed to overestimate MCI in PD patients, as a lower number of patients met criteria when administered a full neuropsychological battery (12) . With this in mind, the MoCA continues to be widely used across many disciplines in clinical and research samples to determine the possibility of cognitive dysfunction in PD-related dementia. Future studies could expand on this by more thoroughly exploring neuropsychological and movement correlates of the ECog, as well as identifying optimal cutpoints to determine the diagnostic sensitivity of this measure in clinical practice with PD and other dementias.
